News
$ニューリックス・セラピューティクス (NRIX.US)$ Nurix Therapeutics (NASDAQ:NRIX) said that the FDA has placed a partial clinical hold on a Phase 1 study of its drug NX-2127 in the treatment of B-cell malignancies as the company’s shifts to a different manufacturing process for the product.
Nurix said patients currently enrolled in the trial who are deriving clinical benefit are allowed to continue receiving the current drug product. The screening and enrollment of new patients has been paused.
The company said it is actively working with the FDA to resolve the hold, which does not affect its other drug programs.
Nurix said patients currently enrolled in the trial who are deriving clinical benefit are allowed to continue receiving the current drug product. The screening and enrollment of new patients has been paused.
The company said it is actively working with the FDA to resolve the hold, which does not affect its other drug programs.
免責事項：このコミュニティは、Moomoo Technologies Inc.が教育目的でのみ提供するものです。
さらに詳しい情報
コメント
サインインコメントをする
